Madison Small Cap Fund Q1 2026 Portfolio Activity

ICU Medical's new high-volume pump adds more connected features, which the article says should support higher retention and incremental revenue. SiteOne Landscape Supply is highlighted as controlling 18% of a $26 billion industry and growing revenue at a low double-digit CAGR. Madison Small Cap Fund also disclosed it liquidated its Globus Medical position after the company's market cap reached $12 billion.

Analysis

ICUI’s angle is less about the pump itself and more about the installed-base monetization flywheel: more connected functionality should raise switching costs, improve workflow lock-in, and extend replacement cycles. If the device meaningfully increases utilization data capture, the larger second-order benefit is not just retention but higher aftermarket mix — software-like economics layered onto a hardware franchise typically supports multiple expansion before the revenue shows up in full.

SITE looks like a steadier compounder than the headline suggests, but the key hidden variable is not market share; it is the persistence of fragmented distribution and customer convenience. In an industry that still has room for professionalization, scale should keep translating into basket expansion, pricing discipline, and better working capital turns. The risk is that the market already treats this as a low-volatility quality story, so upside likely comes from operating leverage rather than multiple rerating.

GMED is the most interesting positioning signal. A multi-year holder exiting after market-cap re-rating can be read as a valuation-driven pause, but it can also indicate that the easiest part of the growth curve is behind it. The consensus may be underestimating how often medtech winners enter a digestion phase once they cross a size threshold: growth can remain solid while incremental upside compresses because new entrants, reimbursement scrutiny, or channel normalization slow the next leg of multiple expansion.

Key Decisions for Investors

• Overweight ICUI on a 3-6 month horizon: buy weakness after the initial launch excitement cools, with a target to own the name ahead of evidence on retention and attach-rate metrics; favorable setup if the stock is still being priced as a device-only story rather than a recurring-revenue platform.
• Long SITE, but prefer a staged entry over 4-8 weeks: the risk/reward is best if macro softness creates a better entry point, since the thesis depends on durable compounding, not a near-term catalyst; use a 12-month horizon and focus on margin durability rather than top-line beats.
• Reduce or hedge GMED exposure into strength: if the stock is trading at a premium growth multiple, consider trimming or overlaying with covered calls over the next 1-2 quarters; the positioning signal suggests valuation risk is now more important than fundamental momentum.